FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Amylyx Pharmaceuticals (AMLX) Announces Pivotal Phase 3 LUCIDITY Trial Design for Avexitide
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
-
-
-
-
-
-
-
Amylyx Pharma (AMLX) Announces Interim Data From Ongoing Phase 2 HELIOS Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

